Armand and coauthors recently reported the exciting results on the use of pembrolizumab, a first-class immune anti-programmed death-1 (PD-1) checkpoint inhibitor (CPi), in pretreated primary mediastinal B-cell lymphoma (PMBCL) (1). They analyzed two consecutive cohorts of patients, namely a subgroup of the phase 1b KEYNOTE-013 trial and of the phase II KEYNOTE-170 trial, involving a total of 74 patients. Enrolled subjects had received three previous lines of therapy (median value) and one-third of them had undergone transplantation. Objective response was reported in 45% (33% complete responses) and 48% (13% complete responses) of patients in the two cohorts, respectively. Median duration of response could not be reached in the first group and was ≥12 months in approximately 75% of cases in the second group. At 12 months, the rate of progression-free survival was 47% and 38% in the two groups, respectively; corresponding figures for overall survival were 65% and 58%, respectively. No special toxicity concerns were reported; 15% of patients experienced grade 3 or 4 toxicities. The most common adverse event was neutropenia, whereas specific CPi-related immune-mediated events occurred in two cases (one grade 4 myositis and one grade 3 pneumonitis).

Overall, PMBCL accounts for 3% of all non-Hodgkin lymphomas (NHLs) and for 10% of all diffuse large B-cell lymphomas (DLBCLs). Although rare, its unique clinical presentation and biological/molecular assessment have stimulated several analyses and papers. Therefore, it is presently one of the best and most deeply known subsets of lymphoma (2,3).

The resemblance of PMBCL with Hodgkin lymphoma (HL) has been described since the last century (4), when an intense debate arose on whether PMBCL should be treated upfront by an HL- or an NHL-oriented approach. Later, when NHL therapy became the dominant therapeutic strategy, an even stronger debate was focused on the choice of chemotherapy regimen, with a more intense MACOP-B (5,6) and derived regimens being considered as “the winners”. The rituximab era changed this point of view, as its addition to any chemotherapy regimen in B-cell lymphomas annulled the difference among different single regimens and improved outcomes (7). Currently, approximately 80% of all cases are cured by first-line treatment.

On the other hand, even during this long period of debate on the choice of first-line treatment, a general agreement remained on the second-line treatment for patients failing or relapsing upon upfront therapy. Even in this setting, the treatment strategy is in line with experiences in DLBCL and consists of second-line chemotherapy followed by autologous stem cell transplantation in chemotherapy-sensitive subjects (8). In fact, this standard approach has historically obtained a worse outcome in PMBCL (9,10) compared with other types of DLBCL. These disappointing results can be attributed to two main reasons: first, approximately two-thirds of recurrent PMBCLs are primary refractory or early relapse, defined as cases who progress during first-line treatment, or those who do not achieve complete remission, or relapse early after the end of upfront therapy (8). Second, both the
overall and complete remission rates are somewhat lower than in classical DLBCL (Table 1), and therefore a lower proportion of patients can proceed with autologous stem cell transplantation (9,10). Remarkably, due to the rarity of the disease and the relatively low incidence of relapse, the above considerations are extrapolated from retrospective and often small series of patients, or from subgroup analyses of randomized trials on DLBCL.

Overall, 20% of subjects with PMBCL will fail first-line therapy and more than half of them will also be refractory to second-line chemotherapy, and therefore an unmet clinical need exists for this setting of patients.

In most hematological malignancies, biological drugs targeting specific biological mechanisms are showing very promising results (15). PMBCL harbors several molecular alterations that may represent the target of novel therapies (16-18). HL and PMBCL present a similar gene-expression profile, harboring genetic alterations of chromosome 9p (16-18). In particular, 9p24.1 is amplified in 53–70% of PMBCL and 30–40% of HLs, but only rarely in DLBCL (19). In PMBCL and HL, amplification of 9p24.1 was observed with both increased PD-L1/2 and cell-surface protein expression. PD-L1 is expressed in 30–80% of PMBCL cases, and the expression of PD-L2 protein is markedly increased in PMBCL. By way of comparison, 70–87% of classical HL and 31–57% of DLBCL express PD-L1 (20). According to the above, genetic alterations at 9p24.1 associates with increased expression of PD-1 ligands, thus conferring sensitivity to CPI (21).

PMBCL harbors several molecular alterations that may represent the target of novel therapies (16-18). HL and PMBCL present a similar gene-expression profile, harboring genetic alterations of chromosome 9p (16-18). In particular, 9p24.1 is amplified in 53–70% of PMBCL and 30–40% of HLs, but only rarely in DLBCL (19). In PMBCL and HL, amplification of 9p24.1 was observed with both increased PD-L1/2 and cell-surface protein expression. PD-L1 is expressed in 30–80% of PMBCL cases, and the expression of PD-L2 protein is markedly increased in PMBCL. By way of comparison, 70–87% of classical HL and 31–57% of DLBCL express PD-L1 (20). According to the above, genetic alterations at 9p24.1 associates with increased expression of PD-1 ligands, thus conferring sensitivity to CPI (21).

CPis are a new revolutionary class of drugs, which act on PD-L1. The activation of PD-1/PD-L1 signaling let tumor cells evade the antigen-specific T-cell immunologic response. Therefore, blocking this checkpoint signaling may represent an effective cancer therapy (22). Pembrolizumab and nivolumab, the two leading drugs of the first CPI generation, have demonstrated substantial activity in several solid and hematological tumors and are now approved for the treatment of several malignancies (23,24).

Besides the presence of 9p24.1 locus alteration, and again as also shown in HL, PD-L1 expression and clinical response of PMBCL to pembrolizumab are related to the magnitude of 9p24 abnormality that determines the PDL-1 expression. In this line, Armand and colleagues performed a biomarker analysis through fluorescence in situ hybridization to assess changes in the gene copy number changes; a modified H-score ranging was thus generated (1). This H-score was defined as the product of the percentage of malignant tumor cells with membranous staining for PD-L1, thus ranging from 0 to 100. In the 42 assessed patients, the rate of objective response was 25% in patients with an H-score of 0, 42% for patients with a of 1–99, and 64% for those with aPD-L1 H-score of 100. PD-L1 expression level was also associated with PFS (1).

Like HL, PMBCL expresses CD30, although more variably. The anti-CD30 antibody drug conjugate brentuximab vedotin, approved in HL, was evaluated in relapsed/refractory PMBCL during a phase II trial. Disappointingly, only a 13% rate of overall response rate was reported, 13% and the trial was thus terminated early (Table 1) (12). Conversely, when brentuximab was associated to a CPI, the magnitude of response rates was higher than the sum of a single-agent performance, and this combination presently represents the most effective

<table>
<thead>
<tr>
<th>Treatment</th>
<th>n (% refr)</th>
<th>ORR (%)</th>
<th>CR (%)</th>
<th>PFS (%)</th>
<th>OS (%)</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>ICE-ASCT</td>
<td>60 (58%)</td>
<td>65</td>
<td>40</td>
<td>57</td>
<td>61</td>
<td>(9)</td>
</tr>
<tr>
<td>Chemo-ASCT</td>
<td>44 (41%)</td>
<td>77</td>
<td>63</td>
<td>70</td>
<td>61</td>
<td>(10)</td>
</tr>
<tr>
<td>Chemo-ASCT</td>
<td>37 (57%)</td>
<td>25</td>
<td>0</td>
<td>15</td>
<td>15</td>
<td>(11)</td>
</tr>
<tr>
<td>BV</td>
<td>15</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>13</td>
<td>(12)</td>
</tr>
<tr>
<td>Pembrolizumab</td>
<td>74</td>
<td>45</td>
<td>13</td>
<td>40</td>
<td>60</td>
<td>(1)</td>
</tr>
<tr>
<td>Nivo/BV</td>
<td>30</td>
<td>73</td>
<td>37</td>
<td>63</td>
<td>86</td>
<td>(13)</td>
</tr>
<tr>
<td>CAR-T</td>
<td>8</td>
<td>70%</td>
<td></td>
<td></td>
<td>50</td>
<td>(14)</td>
</tr>
</tbody>
</table>

PMBCL, primary mediastinal B-cell lymphoma; ASCT, autologous stem cell transplantation; BV, brentuximab vedotin; CR, complete remission; ICE, ifosfamide, carboPt, etoposide; Nivo, nivolumab; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; Refr, refractory.
approach in relapsing/refractory PMBCL. In 30 patients failing at least two previous treatment lines, two-thirds of whom with refractory disease, the association of nivolumab and brentuximab vedotin induced a 73% overall response rate with a 37% rate of CR (13). Median duration of response was not reached, and 11/30 patients were bridged to transplantation. The safety of this combination strategy was acceptable and no additive adverse effects of the two drugs were reported. Given the low activity of brentuximab vedotin as single agent in PMBCL, the authors of that analysis argued that in the combination setting, brentuximab probably exerts its antitumor activity by the depletion of intratumoral T-regulatory cells and the induction of an immunogenic cell death. Both these mechanisms enhance antitumor immunity, which is further boosted by PD-1 blockers (13).

Another approach to be outlined in the therapeutic armamentarium of relapsing-remitting PMBCL is the chimeric antigen receptor (CAR) T cell therapy (14,25). In short, it consists of administration of T lymphocytes modified to express an anti-CD19 chimeric antigen. The outcomes of this strategy in DLBLC have been largely described in the last years (14,25), showing outstanding outcome for cases with high-risk refractory disease. Encouraging data on small number of cases with PMBCL were extrapolated from larger series and further analysis are awaited from ongoing trials to establish the activity of this approach in PMBCL.

To our knowledge, CPis are single agents with the highest activity in PMBCL (Table 1). Their association with classical chemotherapy, as well as with other biological or immunological strategies, are being assessed in prospective ongoing trials at an earlier phase of the clinical history in PMBCL. These trials will obviously represent an interesting challenge in the next years, especially if an appropriate selection of truly high-risk patients will be performed. Indeed, we should not forget that about 80% of PMBCL patients can be cured with standard first-line therapy and, thus, the primary effort must focus on identifying those who probably will not. The need for a specific genetic alteration and the correlation with the amount of the molecular abnormalities reflects the current trend to stratify the choice treatment according to the biological and molecular characteristics of the disease subgroup (1).

**Acknowledgments**

**Funding:** Editorial assistance was provided by Luca Giacomelli, PhD, and Aashni Shah (Polistudium SRL, Milan, Italy), and was supported by internal funds.

**Footnote**

Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/atm.2020.04.06). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

**References**


